Global Eye Infections Treatment

Eye Infections Treatment Comprehensive Study by Type (Gels and Creams, Eye Drops, Drug), Application (Ophthalmology Clinics, Hospitals, Others), Eye Infection (Conjunctivitis or Pink Eye, Viral Keratitis, Fungal Keratitis, Acanthamoeba Keratitis, Trachoma, Endophthalmitis, Other), Symptoms (Red Eyes, Pain, Eye Discharge, Watery Eyes, Dry Eyes, Light Sensitivity, Swollen Eyes, Itching, Blurry Vision, Others) Players and Region - Global Market Outlook to 2030

Eye Infections Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Eye Infections Treatment
Eye infection occurs when harmful microorganisms such as bacteria, fungi and viruses invade any part of the eyeball or surrounding tissues. The most common bacterial eye infections can be effectively treated with prescription antibiotic eye drops or ointments and compresses. In the case of severing viral eye infection, an antiviral eye drop may be prescribed. There are some viral eye infections which require careful administration of steroid eye drops to reduce related inflammation.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR6.1%


The eye infections treatment market is diverse and competitive, with established players and innovative startups shaping the future of treatment options. Focusing on R&D, personalized medicine, and digital health integration is crucial for stakeholders to succeed in this evolving landscape. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Eye Infections Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche Holding AG (Switzerland), Allergan (Ireland), Merck (United States), Novartis (Switzerland), Pfizer (United States), Santen Pharmaceuticals (Japan), Bayer (Germany), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom) and Daiichi Sankyo (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Eli Lilly and Company (United States), Novo Nordisk (Denmark), Sanofi (France) and Alcon Laboratories Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Eye Infections Treatment market by Type (Gels and Creams, Eye Drops and Drug), Application (Ophthalmology Clinics, Hospitals and Others) and Region.



On the basis of geography, the market of Eye Infections Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Eye Infection, the sub-segment i.e. Conjunctivitis or Pink Eye will boost the Eye Infections Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Red Eyes will boost the Eye Infections Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Research and Development Activities

Market Growth Drivers:
Rising Prevalence of Ophthalmic Diseases, Growing Awareness about the Eye Infections and Increasing Air Pollution Leading To Various Eye Problems

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects Associated With Various Antibiotics

Opportunities:
Increasing Geriatric Population Worldwide, Technological Advancements in the Healthcare Sector and Growth in the Healthcare Industry Worldwide

Market Leaders and their expansionary development strategies
In August 2023, Novartis and Allergan announce a collaboration to develop and commercialize novel treatments for eye infections. This partnership represents a significant step forward in the fight against antibiotic-resistant eye infections.
In September 2023, EyeCare America launches its first-ever national marketing campaign to promote its program. Providing free eye exams and eye care services to eligible individuals.


Key Target Audience
Pharmaceutical Companies, Research Institutes, Research Professionals, Distributors, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Gels and Creams
  • Eye Drops
  • Drug
By Application
  • Ophthalmology Clinics
  • Hospitals
  • Others
By Eye Infection
  • Conjunctivitis or Pink Eye
  • Viral Keratitis
  • Fungal Keratitis
  • Acanthamoeba Keratitis
  • Trachoma
  • Endophthalmitis
  • Other

By Symptoms
  • Red Eyes
  • Pain
  • Eye Discharge
  • Watery Eyes
  • Dry Eyes
  • Light Sensitivity
  • Swollen Eyes
  • Itching
  • Blurry Vision
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Ophthalmic Diseases
      • 3.2.2. Growing Awareness about the Eye Infections
      • 3.2.3. Increasing Air Pollution Leading To Various Eye Problems
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Eye Infections Treatment, by Type, Application, Eye Infection, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Eye Infections Treatment (Value)
      • 5.2.1. Global Eye Infections Treatment by: Type (Value)
        • 5.2.1.1. Gels and Creams
        • 5.2.1.2. Eye Drops
        • 5.2.1.3. Drug
      • 5.2.2. Global Eye Infections Treatment by: Application (Value)
        • 5.2.2.1. Ophthalmology Clinics
        • 5.2.2.2. Hospitals
        • 5.2.2.3. Others
      • 5.2.3. Global Eye Infections Treatment by: Eye Infection (Value)
        • 5.2.3.1. Conjunctivitis or Pink Eye
        • 5.2.3.2. Viral Keratitis
        • 5.2.3.3. Fungal Keratitis
        • 5.2.3.4. Acanthamoeba Keratitis
        • 5.2.3.5. Trachoma
        • 5.2.3.6. Endophthalmitis
        • 5.2.3.7. Other
      • 5.2.4. Global Eye Infections Treatment by: Symptoms (Value)
        • 5.2.4.1. Red Eyes
        • 5.2.4.2. Pain
        • 5.2.4.3. Eye Discharge
        • 5.2.4.4. Watery Eyes
        • 5.2.4.5. Dry Eyes
        • 5.2.4.6. Light Sensitivity
        • 5.2.4.7. Swollen Eyes
        • 5.2.4.8. Itching
        • 5.2.4.9. Blurry Vision
        • 5.2.4.10. Others
      • 5.2.5. Global Eye Infections Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Eye Infections Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Santen Pharmaceuticals (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Daiichi Sankyo (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Eye Infections Treatment Sale, by Type, Application, Eye Infection, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Eye Infections Treatment (Value)
      • 7.2.1. Global Eye Infections Treatment by: Type (Value)
        • 7.2.1.1. Gels and Creams
        • 7.2.1.2. Eye Drops
        • 7.2.1.3. Drug
      • 7.2.2. Global Eye Infections Treatment by: Application (Value)
        • 7.2.2.1. Ophthalmology Clinics
        • 7.2.2.2. Hospitals
        • 7.2.2.3. Others
      • 7.2.3. Global Eye Infections Treatment by: Eye Infection (Value)
        • 7.2.3.1. Conjunctivitis or Pink Eye
        • 7.2.3.2. Viral Keratitis
        • 7.2.3.3. Fungal Keratitis
        • 7.2.3.4. Acanthamoeba Keratitis
        • 7.2.3.5. Trachoma
        • 7.2.3.6. Endophthalmitis
        • 7.2.3.7. Other
      • 7.2.4. Global Eye Infections Treatment by: Symptoms (Value)
        • 7.2.4.1. Red Eyes
        • 7.2.4.2. Pain
        • 7.2.4.3. Eye Discharge
        • 7.2.4.4. Watery Eyes
        • 7.2.4.5. Dry Eyes
        • 7.2.4.6. Light Sensitivity
        • 7.2.4.7. Swollen Eyes
        • 7.2.4.8. Itching
        • 7.2.4.9. Blurry Vision
        • 7.2.4.10. Others
      • 7.2.5. Global Eye Infections Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Eye Infections Treatment: by Type(USD Million)
  • Table 2. Eye Infections Treatment Gels and Creams , by Region USD Million (2018-2023)
  • Table 3. Eye Infections Treatment Eye Drops , by Region USD Million (2018-2023)
  • Table 4. Eye Infections Treatment Drug , by Region USD Million (2018-2023)
  • Table 5. Eye Infections Treatment: by Application(USD Million)
  • Table 6. Eye Infections Treatment Ophthalmology Clinics , by Region USD Million (2018-2023)
  • Table 7. Eye Infections Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 8. Eye Infections Treatment Others , by Region USD Million (2018-2023)
  • Table 9. Eye Infections Treatment: by Eye Infection(USD Million)
  • Table 10. Eye Infections Treatment Conjunctivitis or Pink Eye , by Region USD Million (2018-2023)
  • Table 11. Eye Infections Treatment Viral Keratitis , by Region USD Million (2018-2023)
  • Table 12. Eye Infections Treatment Fungal Keratitis , by Region USD Million (2018-2023)
  • Table 13. Eye Infections Treatment Acanthamoeba Keratitis , by Region USD Million (2018-2023)
  • Table 14. Eye Infections Treatment Trachoma , by Region USD Million (2018-2023)
  • Table 15. Eye Infections Treatment Endophthalmitis , by Region USD Million (2018-2023)
  • Table 16. Eye Infections Treatment Other , by Region USD Million (2018-2023)
  • Table 17. Eye Infections Treatment: by Symptoms(USD Million)
  • Table 18. Eye Infections Treatment Red Eyes , by Region USD Million (2018-2023)
  • Table 19. Eye Infections Treatment Pain , by Region USD Million (2018-2023)
  • Table 20. Eye Infections Treatment Eye Discharge , by Region USD Million (2018-2023)
  • Table 21. Eye Infections Treatment Watery Eyes , by Region USD Million (2018-2023)
  • Table 22. Eye Infections Treatment Dry Eyes , by Region USD Million (2018-2023)
  • Table 23. Eye Infections Treatment Light Sensitivity , by Region USD Million (2018-2023)
  • Table 24. Eye Infections Treatment Swollen Eyes , by Region USD Million (2018-2023)
  • Table 25. Eye Infections Treatment Itching , by Region USD Million (2018-2023)
  • Table 26. Eye Infections Treatment Blurry Vision , by Region USD Million (2018-2023)
  • Table 27. Eye Infections Treatment Others , by Region USD Million (2018-2023)
  • Table 28. South America Eye Infections Treatment, by Country USD Million (2018-2023)
  • Table 29. South America Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 30. South America Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 31. South America Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 32. South America Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 33. Brazil Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 34. Brazil Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 35. Brazil Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 36. Brazil Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 37. Argentina Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 38. Argentina Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 39. Argentina Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 40. Argentina Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 41. Rest of South America Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 42. Rest of South America Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 43. Rest of South America Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 44. Rest of South America Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 45. Asia Pacific Eye Infections Treatment, by Country USD Million (2018-2023)
  • Table 46. Asia Pacific Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 47. Asia Pacific Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 49. Asia Pacific Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 50. China Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 51. China Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 52. China Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 53. China Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 54. Japan Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 55. Japan Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 56. Japan Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 57. Japan Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 58. India Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 59. India Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 60. India Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 61. India Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 62. South Korea Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 63. South Korea Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 64. South Korea Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 65. South Korea Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 66. Taiwan Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 67. Taiwan Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 68. Taiwan Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 69. Taiwan Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 70. Australia Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 71. Australia Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 72. Australia Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 73. Australia Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 78. Europe Eye Infections Treatment, by Country USD Million (2018-2023)
  • Table 79. Europe Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 80. Europe Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 81. Europe Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 82. Europe Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 83. Germany Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 84. Germany Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 85. Germany Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 86. Germany Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 87. France Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 88. France Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 89. France Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 90. France Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 91. Italy Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 92. Italy Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 93. Italy Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 94. Italy Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 95. United Kingdom Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 96. United Kingdom Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 97. United Kingdom Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 98. United Kingdom Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 99. Netherlands Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 100. Netherlands Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 101. Netherlands Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 102. Netherlands Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 103. Rest of Europe Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 104. Rest of Europe Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 105. Rest of Europe Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 106. Rest of Europe Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 107. MEA Eye Infections Treatment, by Country USD Million (2018-2023)
  • Table 108. MEA Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 109. MEA Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 110. MEA Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 111. MEA Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 112. Middle East Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 113. Middle East Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 114. Middle East Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 115. Middle East Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 116. Africa Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 117. Africa Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 118. Africa Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 119. Africa Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 120. North America Eye Infections Treatment, by Country USD Million (2018-2023)
  • Table 121. North America Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 122. North America Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 123. North America Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 124. North America Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 125. United States Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 126. United States Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 127. United States Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 128. United States Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 129. Canada Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 130. Canada Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 131. Canada Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 132. Canada Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 133. Mexico Eye Infections Treatment, by Type USD Million (2018-2023)
  • Table 134. Mexico Eye Infections Treatment, by Application USD Million (2018-2023)
  • Table 135. Mexico Eye Infections Treatment, by Eye Infection USD Million (2018-2023)
  • Table 136. Mexico Eye Infections Treatment, by Symptoms USD Million (2018-2023)
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Eye Infections Treatment: by Type(USD Million)
  • Table 148. Eye Infections Treatment Gels and Creams , by Region USD Million (2025-2030)
  • Table 149. Eye Infections Treatment Eye Drops , by Region USD Million (2025-2030)
  • Table 150. Eye Infections Treatment Drug , by Region USD Million (2025-2030)
  • Table 151. Eye Infections Treatment: by Application(USD Million)
  • Table 152. Eye Infections Treatment Ophthalmology Clinics , by Region USD Million (2025-2030)
  • Table 153. Eye Infections Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 154. Eye Infections Treatment Others , by Region USD Million (2025-2030)
  • Table 155. Eye Infections Treatment: by Eye Infection(USD Million)
  • Table 156. Eye Infections Treatment Conjunctivitis or Pink Eye , by Region USD Million (2025-2030)
  • Table 157. Eye Infections Treatment Viral Keratitis , by Region USD Million (2025-2030)
  • Table 158. Eye Infections Treatment Fungal Keratitis , by Region USD Million (2025-2030)
  • Table 159. Eye Infections Treatment Acanthamoeba Keratitis , by Region USD Million (2025-2030)
  • Table 160. Eye Infections Treatment Trachoma , by Region USD Million (2025-2030)
  • Table 161. Eye Infections Treatment Endophthalmitis , by Region USD Million (2025-2030)
  • Table 162. Eye Infections Treatment Other , by Region USD Million (2025-2030)
  • Table 163. Eye Infections Treatment: by Symptoms(USD Million)
  • Table 164. Eye Infections Treatment Red Eyes , by Region USD Million (2025-2030)
  • Table 165. Eye Infections Treatment Pain , by Region USD Million (2025-2030)
  • Table 166. Eye Infections Treatment Eye Discharge , by Region USD Million (2025-2030)
  • Table 167. Eye Infections Treatment Watery Eyes , by Region USD Million (2025-2030)
  • Table 168. Eye Infections Treatment Dry Eyes , by Region USD Million (2025-2030)
  • Table 169. Eye Infections Treatment Light Sensitivity , by Region USD Million (2025-2030)
  • Table 170. Eye Infections Treatment Swollen Eyes , by Region USD Million (2025-2030)
  • Table 171. Eye Infections Treatment Itching , by Region USD Million (2025-2030)
  • Table 172. Eye Infections Treatment Blurry Vision , by Region USD Million (2025-2030)
  • Table 173. Eye Infections Treatment Others , by Region USD Million (2025-2030)
  • Table 174. South America Eye Infections Treatment, by Country USD Million (2025-2030)
  • Table 175. South America Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 176. South America Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 177. South America Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 178. South America Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 179. Brazil Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 180. Brazil Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 181. Brazil Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 182. Brazil Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 183. Argentina Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 184. Argentina Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 185. Argentina Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 186. Argentina Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 187. Rest of South America Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 188. Rest of South America Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 189. Rest of South America Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 190. Rest of South America Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 191. Asia Pacific Eye Infections Treatment, by Country USD Million (2025-2030)
  • Table 192. Asia Pacific Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 193. Asia Pacific Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 194. Asia Pacific Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 195. Asia Pacific Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 196. China Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 197. China Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 198. China Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 199. China Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 200. Japan Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 201. Japan Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 202. Japan Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 203. Japan Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 204. India Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 205. India Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 206. India Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 207. India Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 208. South Korea Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 209. South Korea Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 210. South Korea Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 211. South Korea Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 212. Taiwan Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 213. Taiwan Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 214. Taiwan Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 215. Taiwan Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 216. Australia Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 217. Australia Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 218. Australia Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 219. Australia Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 220. Rest of Asia-Pacific Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 221. Rest of Asia-Pacific Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 222. Rest of Asia-Pacific Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 223. Rest of Asia-Pacific Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 224. Europe Eye Infections Treatment, by Country USD Million (2025-2030)
  • Table 225. Europe Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 226. Europe Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 227. Europe Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 228. Europe Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 229. Germany Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 230. Germany Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 231. Germany Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 232. Germany Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 233. France Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 234. France Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 235. France Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 236. France Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 237. Italy Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 238. Italy Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 239. Italy Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 240. Italy Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 241. United Kingdom Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 242. United Kingdom Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 243. United Kingdom Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 244. United Kingdom Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 245. Netherlands Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 246. Netherlands Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 247. Netherlands Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 248. Netherlands Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 249. Rest of Europe Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 250. Rest of Europe Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 251. Rest of Europe Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 252. Rest of Europe Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 253. MEA Eye Infections Treatment, by Country USD Million (2025-2030)
  • Table 254. MEA Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 255. MEA Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 256. MEA Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 257. MEA Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 258. Middle East Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 259. Middle East Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 260. Middle East Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 261. Middle East Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 262. Africa Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 263. Africa Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 264. Africa Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 265. Africa Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 266. North America Eye Infections Treatment, by Country USD Million (2025-2030)
  • Table 267. North America Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 268. North America Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 269. North America Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 270. North America Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 271. United States Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 272. United States Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 273. United States Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 274. United States Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 275. Canada Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 276. Canada Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 277. Canada Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 278. Canada Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 279. Mexico Eye Infections Treatment, by Type USD Million (2025-2030)
  • Table 280. Mexico Eye Infections Treatment, by Application USD Million (2025-2030)
  • Table 281. Mexico Eye Infections Treatment, by Eye Infection USD Million (2025-2030)
  • Table 282. Mexico Eye Infections Treatment, by Symptoms USD Million (2025-2030)
  • Table 283. Research Programs/Design for This Report
  • Table 284. Key Data Information from Secondary Sources
  • Table 285. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Eye Infections Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Eye Infections Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Eye Infections Treatment: by Eye Infection USD Million (2018-2023)
  • Figure 7. Global Eye Infections Treatment: by Symptoms USD Million (2018-2023)
  • Figure 8. South America Eye Infections Treatment Share (%), by Country
  • Figure 9. Asia Pacific Eye Infections Treatment Share (%), by Country
  • Figure 10. Europe Eye Infections Treatment Share (%), by Country
  • Figure 11. MEA Eye Infections Treatment Share (%), by Country
  • Figure 12. North America Eye Infections Treatment Share (%), by Country
  • Figure 13. Global Eye Infections Treatment share by Players 2023 (%)
  • Figure 14. Global Eye Infections Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Eye Infections Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 21. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck (United States) Revenue: by Geography 2023
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2023
  • Figure 27. Santen Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Santen Pharmaceuticals (Japan) Revenue: by Geography 2023
  • Figure 29. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Bayer (Germany) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 33. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Daiichi Sankyo (Japan) Revenue: by Geography 2023
  • Figure 37. Global Eye Infections Treatment: by Type USD Million (2025-2030)
  • Figure 38. Global Eye Infections Treatment: by Application USD Million (2025-2030)
  • Figure 39. Global Eye Infections Treatment: by Eye Infection USD Million (2025-2030)
  • Figure 40. Global Eye Infections Treatment: by Symptoms USD Million (2025-2030)
  • Figure 41. South America Eye Infections Treatment Share (%), by Country
  • Figure 42. Asia Pacific Eye Infections Treatment Share (%), by Country
  • Figure 43. Europe Eye Infections Treatment Share (%), by Country
  • Figure 44. MEA Eye Infections Treatment Share (%), by Country
  • Figure 45. North America Eye Infections Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Holding AG (Switzerland)
  • Allergan (Ireland)
  • Merck (United States)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Santen Pharmaceuticals (Japan)
  • Bayer (Germany)
  • GlaxoSmithKline (United Kingdom)
  • AstraZeneca (United Kingdom)
  • Daiichi Sankyo (Japan)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States) , Novo Nordisk (Denmark) , Sanofi (France) , Alcon Laboratories Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 221 Pages 97 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Eye Infections Treatment Quantitative research analysis
Global Eye Infections Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche Holding AG (Switzerland), Allergan (Ireland), Merck (United States), Novartis (Switzerland), Pfizer (United States), Santen Pharmaceuticals (Japan), Bayer (Germany), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom) and Daiichi Sankyo (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Research and Development Activities" is seen as one of major influencing trends for Eye Infections Treatment Market during projected period 2023-2030.
The Eye Infections Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Eye Infections Treatment Report?

Have a Query? Click Here

Other Related Reports

Allopurinol Tablets Comprehensive Study by Type (100 mg, 300 mg), Application (Healthcare Industry, Hospitals), Distribution Channel (Hospitals, Pharma Retail, Clinics, Others), Side Effects (Nausea,...
$ 3350
Urethritis Drugs Comprehensive Study by Type (Gonococcal Urethritis, Non gonococcal Urethritis), End-users (Hospitals and Clinics, Research and Academics, Others), Drugs Treatment (Antivirals, Anti-B...
$ 3800
Anti-Venom Comprehensive Study by Type (Snake Anti-Venom, Scorpion Anti-Venom, Spider Anti-Venom, Others), Mode of Action (Cytotoxic, Neurotoxic, Haemotoxic, Cardiotoxic, Myotoxic, Others), Antivenom...
$ 3750
Low Molecular Weight Heparin (LMWHs) Comprehensive Study by Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine), Application (Treatment of Venous Thromboembolism, Complications of Pregnancy, Anti-...
$ 3750
Tongkat Ali Powder Comprehensive Study by Type (Tongkat Ali Root Extract Powder, Tongkat Ali Extract Powder, Tongkat Ali Powder, Tongkat Ali Powder Medicine for Sexual Power), Application (Personal U...
$ 3450
Genital Herpes Treatment Comprehensive Study by Type (Acyclovir, Valacyclovir, Famciclovir), Application (HSV-1, HSV-2), Route of Administration (Oral, Topical, Injectable), Distribution Channel (Hos...
$ 3450